RPGLIFE
RPG Life Sciences Limited
Branded generics, generics and APIs for gastroenterology and neuropsychiatry
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
rpglifesciences.com(opens the company website in a new tab)Key metrics
Price as of 2026-10-16
Full years shown; sign in free for the trailing twelve months. Learn about these metrics →
Price & valuation
Share price and valuation multiples (P/E, P/B and more) over time.
Loading price history…
Compare with peers
Loading peers…
What you need to know
RPG Life Sciences makes and sells branded prescription medicines, mainly in India and Nepal, and also exports formulations and sells active pharmaceutical ingredients (APIs) to pharma companies in India and abroad.
Company snapshot
61stBy market cap
Ranked among 119 companies in Pharmaceuticals.
What we see
- ✓Net margin of 16.3% — the business keeps a healthy share of every rupee it earns.
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Sales | 180 Cr | 177 Cr | 196 Cr |
| Operating expenses (approx.) | 140 Cr | 144 Cr | 152 Cr |
| EBITDA | 40 Cr | 33 Cr | 43 Cr |
| OPM % | 22.1% | 18.6% | 22.1% |
| Other income | 3 Cr | 12 Cr | 5 Cr |
| Interest | 0.25 Cr | 0.39 Cr | 0.63 Cr |
| Depreciation | 5 Cr | 6 Cr | 6 Cr |
| Profit before tax | 29 Cr | 40 Cr | 41 Cr |
| Tax % | 24.0% | 25.6% | 25.8% |
| Net profit | 22 Cr | 30 Cr | 31 Cr |
| EPS (₹) | ₹13.38 | ₹18.08 | ₹18.60 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2026 | TTM |
|---|---|---|
| Sales | 708 Cr | Sign in free for the trailing twelve months |
| Operating expenses (approx.) | 560 Cr | Sign in free for the trailing twelve months |
| EBITDA | 147 Cr | Sign in free for the trailing twelve months |
| OPM % | 20.8% | Sign in free for the trailing twelve months |
| Other income | 26 Cr | Sign in free for the trailing twelve months |
| Interest | 0.89 Cr | Sign in free for the trailing twelve months |
| Depreciation | 21 Cr | Sign in free for the trailing twelve months |
| Profit before tax | 154 Cr | Sign in free for the trailing twelve months |
| Tax % | 25.3% | Sign in free for the trailing twelve months |
| Net profit | 115 Cr | Sign in free for the trailing twelve months |
| EPS (₹) | ₹18.08 | Sign in free for the trailing twelve months |
| Dividend payout % | 34.5% | Sign in free for the trailing twelve months |
The latest four quarters added up, next to each full year
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2026 |
|---|---|
| Equity capital | 13 Cr |
| Reserves | 592 Cr |
| Borrowings | 20 Cr |
| Other liabilities | 168 Cr |
| Total liabilities | 793 Cr |
| Fixed assets (net) | 192 Cr |
| CWIP | 20 Cr |
| Investments | 85 Cr |
| Loans & advances | 9 Cr |
| Inventories | 124 Cr |
| Trade receivables | 117 Cr |
| Cash & bank | 150 Cr |
| Other assets | 96 Cr |
| Total assets | 793 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2026 |
|---|---|
| Cash from operating activity | 57 Cr |
| Cash from investing | 86 Cr |
| Cash from financing | -21 Cr |
| Net cash flow | 122 Cr |
| Free cash flow (OCF − Capex) | -9 Cr |
Ratios
| Metric | Mar 2026 |
|---|---|
| ROCE % | 24.8% |
| ROE % | 19.0% |
| Debtor days | 60 |
| Inventory days | 332 |
| Days payable | 260 |
| Cash conversion cycle | 131 |
| OCF / EBITDA % | 38.4% |
| Debt / equity | 0.03 |
| Current ratio | 3.52 |
| Net debt / EBITDA | -0.89 |